Ulcerative Colitis Therapeutics Market
Ulcerative Colitis Therapeutics Market Analysis By Disease Type (Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis), By Route of Administration (Oral, Injectables) & By Region - Global Market Insights 2021 to 2027
Analysis of Ulcerative Colitis Therapeutics market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Ulcerative Colitis Therapeutics Market Outlook (2021 to 2027)
The global ulcerative colitis therapeutics market is anticipated to rise at a CAGR of 5.1% from 2021 to 2027. In 2020, revenue from ulcerative colitis therapeutics was US$ 5.6 Bn, which is expected to reach US$ 7.9 Bn by 2027.
| Report Attributes | Details |
|---|---|
| Market Size (2020) | US$ 5.6 Bn |
| Projected Year Value (2027) | US$ 7.9 Bn |
| Global Market Growth Rate (2021 to 2027) | 5.1% CAGR |
| China Market Growth Rate (2021 to 2027) | 4.8% |
| Key Companies Profiled | Abbott Laboratories, Inc.; AstraZeneca PLC; Avaxia Biologics, Inc.; BioLineRx Ltd.; Astellas Pharma, Inc.; Cosmo Pharmaceuticals NV; AbbVie, Inc.; Amgen, Inc. |
The ulcerative proctitis segment is projected to increase at a 4.7% CAGR from 2021 to 2027.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Demand Analysis of Ulcerative Colitis Therapeutics from 2017 to 2020 Vs Market Outlook for 2021 to 2027
“Increasing Prevalence of Ulcerative Colitis to Fuel Market Revenue”
The global market for ulcerative colitis therapeutics was valued at US$ 5.6 Bn in 2020.
Ulcerative colitis is a type of inflammatory bowel disease that affects a large number of people. It causes ulcers and inflammation in the digestive tract. The innermost lining of the large intestine and the rectum are affected by ulcerative colitis.
Ulcerative colitis can strike anyone at any age; however, it is most frequent in persons aged 15 to 30. The symptoms of ulcerative colitis differ from person to person, but they may include diarrhea, blood in the stool, and immunological response in the abdomen.
Abdominal cramping, nausea, fever, skin ulcers, loss of appetite, weight loss, joint pain, and weariness are all signs of ulcerative colitis. Hemorrhage, colon rupture, and the development of colon cancer are all serious complications of ulcerative colitis.
Around 20% of persons with ulcerative colitis or Crohn's disease, which is also a kind of IBD, have a family relative who has the condition. There is currently no cure for ulcerative colitis. However, some treatments can help to lessen the signs and symptoms of ulcerative colitis and perhaps bring about long-term remission.
Due to an increase in the frequency of ulcerative colitis and increased research and development to produce revolutionary ulcerative colitis treatments, the global ulcerative colitis therapeutics market is predicted to grow significantly.
All of these factors are expected to drive the market at 5.1% CAGR from 2021 to 2027.
Which Key Market Contributors are Driving Demand for Ulcerative Colitis Therapeutics?
“Continuous Advancements in Novel Treatments Boosting Market Growth”
The existence of enhanced ulcerative colitis therapies as a result of recent advancements, as well as the growing patient pool in need of treatment, are two main catalytic drivers driving the ulcerative colitis market forward.
Increased demand for symptomatic treatments, the influx of enhancing medications into the market, and increased acceptance of steroids and biologics to treat ulcerative colitis are all contributing to the industry growth.
Due to increased demand for ulcerative colitis therapeutic drugs, a shortage of medication, tailored therapy, and curative therapy for ulcerative colitis, the ulcerative colitis industry is likely to offer attractive market prospects.
Increased research and development efforts by public and private healthcare institutions are likely to increase opportunities for ulcerative colitis market participants.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
What are the Challenging Factors for Market Expansion?
“Unfavorable Legislations & Expiration of Drug Patents Hampering Market Value Growth”
The market for ulcerative colitis therapeutics is projected to be constrained by the expiration of drug patents and strict government norms and regulations for biosimilar licensing. The market is additionally hampered by unfavorable legislation and policies, as well as varying circumstances in different nations.
Lack of understanding of the disease, and significant limitations of existing therapy choices could all operate as roadblocks for ulcerative colitis therapeutic solutions providers.
Which Region Dominates the Global Ulcerative Colitis Therapeutics Market?
“Rising Demand for Advanced Medical Technologies Driving Industry Growth in North America”
North America is likely to lead the ulcerative colitis therapeutics market because of the presence of prominent players and the rising frequency of ulcerative colitis in the region, as well as continued financing for the discovery of new therapies for the treatment of diseases.
The market is growing due to the rising demand for novel medical technologies and the presence of adequate medical facilities.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Country-wise Insights
Why is the U.S. an Important Market for Ulcerative Colitis Therapeutic Drug Providers?
“High Availability of Treatment Choices Stimulating Market Expansion”
The U.S. ulcerative colitis therapeutics market was valued at US$ 1.7 Bn in 2020 and is projected to increase at the highest CAGR over the forecast period. In the United States, ulcerative colitis affects between 250,000 and 500,000 people, with an annual incidence of 8 to 12 per 100,000 people that has been stable over the last five decades.
The market is expected to grow significantly over the projected period due to wide availability of treatment choices, high healthcare spending, prevalence of diagnostic techniques that lead to early disease diagnosis, and an established healthcare system.
What is the Outlook for the China Ulcerative Colitis Therapeutics Market?
“Significant Healthcare Expenditure by Government Entities to Boost Market Value”
The market in China is expected to reach a valuation of US$ 1.4 Bn by 2027, representing a 4.8% CAGR from 2021 to 2027. The market in China is expected to be highly attractive over the forecast period, due to increased product approvals and high disposable income.
Market growth is being driven by a growing focus on developing healthcare facilities, economic growth, enhanced healthcare services, and the government's supportive policies.
Category-wise Insights
Which Disease Type Shows the Highest Potential for Ulcerative Colitis Therapeutics?
“Innovative Therapeutics for Ulcerative Proctitis Driving Market Revenue”
The ulcerative proctitis segment is projected to record a 4.7% CAGR and reach US$ 2.1 Bn over the forecast period. One of the types of ulcerative colitis is ulcerative proctitis. Fine ulcerations in the inner linings of the large intestine mucosa are visible, and it is thought to be the first sign of ulcerative proctitis.
The segment is expected to grow due to increased research & development initiatives in the discovery of innovative therapeutics for ulcerative proctitis. Market revenue is being boosted by a growth in the number of inflammatory bowel diseases, ulcerative proctitis diseases, and the development of new ulcerative proctitis medications in clinical laboratories.
Which Route of Administration Enjoys High Preference?
“Oral Route of Administration More Preferred Owing to Strong Presence of Oral Pipeline Products”
The oral route of administration is expected to grow at the fastest rate over the forecast period. The approval of innovative medications for the treatment of ulcerative colitis, as well as the strong presence of oral pipeline products for the treatment of ulcerative colitis, have contributed to the segment growth.
Because of increased R&D efforts in the pharmaceutical and medical device industries, increased demand for pharmaceuticals required for treatment, and increased use of various types of ulcerative colitis drugs, the oral route of administration segment is expected to grow significantly.
Competitive Landscape
The market for ulcerative colitis therapeutics is highly competitive. Certain strategic efforts, such as mergers, new product launches, acquisitions, and collaborations, are implemented by key players to help them increase their market position.
For instance :
- In May 2021, The U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb's Zeposia (ozanimod) for the treatment of individuals with moderately to highly active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD).
Key Segments Covered in Ulcerative Colitis Therapeutics Industry Research
-
By Disease Type :
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
-
By Route of Administration :
- Oral
- Injectables
-
By Region :
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Key Market Trends
- 4. Key Success Factors
- 5. Market Background
- 6. Global Market Volume (Units) Analysis 2017 to 2020 and Forecast, 2021 to 2027
- 7. Global Market - Pricing Analysis
- 8. Global Market Value Analysis 2017 to 2020 and Forecast, 2021 to 2027
- 9. Global Market Analysis 2017 to 2020 and Forecast 2021 to 2027, by Disease Type
- 9.1. Ulcerative Proctitis
- 9.2. Proctosigmoiditis
- 9.3. Left-sided Colitis
- 9.4. Pancolitis or Universal Colitis
- 9.5. Fulminant Colitis
- 10. Global Market Analysis 2017 to 2020 and Forecast 2021 to 2027, by Route of Administration
- 10.1. Oral
- 10.2. Injectables
- 11. Global Market Analysis 2017 to 2020 and Forecast 2021 to 2027, by Region
- 11.1. North America
- 11.2. Latin America
- 11.3. Europe
- 11.4. East Asia
- 11.5. South Asia
- 11.6. Oceania
- 11.7. Middle East and Africa (MEA)
- 12. North America Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 13. Latin America Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 14. Europe Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 15. South Asia Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 16. East Asia Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 17. Oceania Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 18. Middle East and Africa Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 19. Key and Emerging Countries Market Analysis 2017 to 2020 and Forecast 2021 to 2027
- 20. Market Structure Analysis
- 21. Competition Analysis
- 21.1. Abbott Laboratories, Inc.
- 21.2. AstraZeneca PLC
- 21.3. Avaxia Biologics, Inc.
- 21.4. BioLineRx Ltd.
- 21.5. Astellas Pharma, Inc.
- 21.6. Cosmo Pharmaceuticals NV
- 21.7. AbbVie, Inc.
- 21.8. Amgen, Inc.
- 22. Assumptions and Acronyms Used
- 23. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Volume (‘000 Units) Analysis and Opportunity Assessment 2017 to 2027, By Disease Type
Table 02: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Disease Type
Table 03: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Route of Administration
Table 04: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Region
Table 05: North America Market Value (US$ Mn) Analysis 2017 to 2020 and Forecast 2021 to 2027, By Country
Table 06: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Disease Type
Table 07: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Route of Administration
Table 08: Latin America Market Value (US$ Mn) Analysis 2017 to 2020 and Forecast 2021 to 2027, By Country
Table 09: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Disease Type
Table 10: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Route of Administration
Table 11: Europe Market Value (US$ Mn) Analysis 2017 to 2020 and Forecast 2021 to 2027, By Country
Table 12: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Disease Type
Table 13: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Route of Administration
Table 14: South Asia Market Value (US$ Mn) Analysis 2017 to 2020 and Forecast 2021 to 2027, By Country
Table 15: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Disease Type
Table 16: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Route of Administration
Table 17: East Asia Market Value (US$ Mn) Analysis 2017 to 2020 and Forecast 2021 to 2027, By Country
Table 18: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Disease Type
Table 19: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Route of Administration
Table 20: Oceania Market Value (US$ Mn) Analysis 2017 to 2020 and Forecast 2021 to 2027, By Country
Table 21: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Disease Type
Table 22: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Route of Administration
Table 23: Middle East and Africa Market Value (US$ Mn) Analysis 2017 to 2020 and Forecast 2021 to 2027, By Country
Table 24: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Disease Type
Table 25: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2027, By Route of Administration
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Volume (in 000' Units) Analysis, 2017 to 2020
Figure 02: Global Market Volume Forecast (in 000' Units), 2021 to 2027
Figure 03: Pricing Analysis (US$) Per Product, By Region, 2020
Figure 04: Pricing Analysis (US$) Per Product, By Region, 2020
Figure 05: Global Market Value Analysis (US$ Mn), 2017 to 2020
Figure 06: Global Market Value Forecast (US$ Mn), 2021 to 2027
Figure 07: Global Market Absolute $ Opportunity, 2021 to 2027
Figure 08: Global Market Share Analysis (%), By Disease Type, 2021 to 2027
Figure 09: Global Market Y-o-Y Analysis (%), By Disease Type, 2021 to 2027
Figure 10: Global Market Attractiveness Analysis by Disease Type, 2021 to 2027
Figure 11: Global Market Share Analysis (%), By Route of Administration, 2021 to 2027
Figure 12: Global Market Y-o-Y Analysis (%), By Route of Administration, 2021 to 2027
Figure 13: Global Market Attractiveness Analysis by Route of Administration, 2021 to 2027
Figure 14: Global Market Share Analysis (%), By Region, 2021 to 2027
Figure 15: Global Market Y-o-Y Analysis (%), By Region, 2021 to 2027
Figure 16: Global Market Attractiveness Analysis by Region, 2021 to 2027
Figure 17: North America Market Value Share, By Disease Type, 2021 (E)
Figure 18: North America Market Value Share, By Route of Administration, 2021 (E)
Figure 19: North America Market Value Share, By Country, 2021 (E)
Figure 20: North America Market Value Analysis (US$ Mn), 2017 to 2020
Figure 21: North America Market Value Forecast (US$ Mn), 2021 to 2027
Figure 22: North America Market Attractiveness Analysis by Disease Type, 2021 to 2027
Figure 23: North America Market Attractiveness Analysis by Route of Administration, 2021 to 2027
Figure 24: North America Market Attractiveness Analysis by Country, 2021 to 2027
Figure 25: Latin America Market Value Share, By Disease Type, 2021 (E)
Figure 26: Latin America Market Value Share, By Route of Administration, 2021 (E)
Figure 27: Latin America Market Value Share, By Country, 2021 (E)
Figure 28: Latin America Market Value Analysis (US$ Mn), 2017 to 2020
Figure 29: Latin America Market Value Forecast (US$ Mn), 2021 to 2027
Figure 30: Latin America Market Attractiveness Analysis by Disease Type, 2021 to 2027
Figure 31: Latin America Market Attractiveness Analysis by Route of Administration, 2021 to 2027
Figure 32: Latin America Market Attractiveness Analysis by Country, 2021 to 2027
Figure 33: Europe Market Value Share, By Disease Type, 2021 (E)
Figure 34: Europe Market Value Share, By Route of Administration, 2021 (E)
Figure 35: Europe Market Value Share, By Country, 2021 (E)
Figure 36: Europe Market Value Analysis (US$ Mn), 2017 to 2020
Figure 37: Europe Market Value Forecast (US$ Mn), 2021 to 2027
Figure 38: Europe Market Attractiveness Analysis by Disease Type, 2021 to 2027
Figure 39: Europe Market Attractiveness Analysis by Route of Administration, 2021 to 2027
Figure 40: Europe Market Attractiveness Analysis by Country, 2021 to 2027
Figure 41: South Asia Market Value Share, By Disease Type, 2021 (E)
Figure 42: South Asia Market Value Share, By Route of Administration, 2021 (E)
Figure 43: South Asia Market Value Share, By Country, 2021 (E)
Figure 44: South Asia Market Value Analysis (US$ Mn), 2017 to 2020
Figure 45: South Asia Market Value Forecast (US$ Mn), 2021 to 2027
Figure 46: South Asia Market Attractiveness Analysis by Disease Type, 2021 to 2027
Figure 47: South Asia Market Attractiveness Analysis by Route of Administration, 2021 to 2027
Figure 48: South Asia Market Attractiveness Analysis by Country, 2021 to 2027
Figure 49: East Asia Market Value Share, By Disease Type, 2021 (E)
Figure 50: East Asia Market Value Share, By Route of Administration, 2021 (E)
Figure 51: East Asia Market Value Share, By Country, 2021 (E)
Figure 52: East Asia Market Value Analysis (US$ Mn), 2017 to 2020
Figure 53: East Asia Market Value Forecast (US$ Mn), 2021 to 2027
Figure 54: East Asia Market Attractiveness Analysis by Disease Type, 2021 to 2027
Figure 55: East Asia Market Attractiveness Analysis by Route of Administration, 2021 to 2027
Figure 56: East Asia Market Attractiveness Analysis by Country, 2021 to 2027
Figure 57: Oceania Market Value Share, By Disease Type, 2021 (E)
Figure 58: Oceania Market Value Share, By Route of Administration, 2021 (E)
Figure 59: Oceania Market Value Share, By Country, 2021 (E)
Figure 60: Oceania Market Value Analysis (US$ Mn), 2017 to 2020
Figure 61: Oceania Market Value Forecast (US$ Mn), 2021 to 2027
Figure 62: Oceania Market Attractiveness Analysis by Disease Type, 2021 to 2027
Figure 63: Oceania Market Attractiveness Analysis by Route of Administration, 2021 to 2027
Figure 64: Oceania Market Attractiveness Analysis by Country, 2021 to 2027
Figure 65: Middle East and Africa Market Value Share, By Disease Type, 2021 (E)
Figure 66: Middle East and Africa Market Value Share, By Route of Administration, 2021 (E)
Figure 67: Middle East and Africa Market Value Share, By Country, 2021 (E)
Figure 68: Middle East and Africa Market Value Analysis (US$ Mn), 2017 to 2020
Figure 69: Middle East and Africa Market Value Forecast (US$ Mn), 2021 to 2027
Figure 70: Middle East and Africa Market Attractiveness Analysis by Disease Type, 2021 to 2027
Figure 71: Middle East and Africa Market Attractiveness Analysis by Route of Administration, 2021 to 2027
Figure 72: Middle East and Africa Market Attractiveness Analysis by Country, 2021 to 2027
Figure 73: U. S. Market Value Analysis (US$ Mn), 2021 & 2027
Figure 74: U. S. Market Value Share, By Disease Type, 2021 (E)
Figure 75: U. S. Market Value Share, By Route of Administration, 2021 (E)
Figure 76: Canada Market Value Analysis (US$ Mn), 2021 & 2027
Figure 77: Canada Market Value Share, By Disease Type, 2021 (E)
Figure 78: Canada Market Value Share, By Route of Administration, 2021 (E)
Figure 79: Mexico Market Value Analysis (US$ Mn), 2021 & 2027
Figure 80: Mexico Market Value Share, By Disease Type, 2021 (E)
Figure 81: Mexico Market Value Share, By Route of Administration, 2021 (E)
Figure 82: Brazil Market Value Analysis (US$ Mn), 2021 & 2027
Figure 83: Brazil Market Value Share, By Disease Type, 2021 (E)
Figure 84: Brazil Market Value Share, By Route of Administration, 2021 (E)
Figure 85: U. K. Market Value Analysis (US$ Mn), 2021 & 2027
Figure 86: U. K. Market Value Share, By Disease Type, 2021 (E)
Figure 87: U. K. Market Value Share, By Route of Administration, 2021 (E)
Figure 88: Germany Market Value Analysis (US$ Mn), 2021 & 2027
Figure 89: Germany Market Value Share, By Disease Type, 2021 (E)
Figure 90: Germany Market Value Share, By Route of Administration, 2021 (E)
Figure 91: France Market Value Analysis (US$ Mn), 2021 & 2027
Figure 92: France Market Value Share, By Disease Type, 2021 (E)
Figure 93: France Market Value Share, By Route of Administration, 2021 (E)
Figure 94: Italy Market Value Analysis (US$ Mn), 2021 & 2027
Figure 95: Italy Market Value Share, By Disease Type, 2021 (E)
Figure 96: Italy Market Value Share, By Route of Administration, 2021 (E)
Figure 97: Spain Market Value Analysis (US$ Mn), 2021 & 2027
Figure 98: Spain Market Value Share, By Disease Type, 2021 (E)
Figure 99: Spain Market Value Share, By Route of Administration, 2021 (E)
Figure 100: Russia Market Value Analysis (US$ Mn), 2021 & 2027
Figure 101: Russia Market Value Share, By Disease Type, 2021 (E)
Figure 102: Russia Market Value Share, By Route of Administration, 2021 (E)
Figure 103: China Market Value Analysis (US$ Mn), 2021 & 2027
Figure 104: China Market Value Share, By Disease Type, 2021 (E)
Figure 105: China Market Value Share, By Route of Administration, 2021 (E)
Figure 106: Japan Market Value Analysis (US$ Mn), 2021 & 2027
Figure 107: Japan Market Value Share, By Disease Type, 2021 (E)
Figure 108: Japan Market Value Share, By Route of Administration, 2021 (E)
Figure 109: South Korea Market Value Analysis (US$ Mn), 2021 & 2027
Figure 110: South Korea Market Value Share, By Disease Type, 2021 (E)
Figure 111: South Korea Market Value Share, By Route of Administration, 2021 (E)
Figure 112: India Market Value Analysis (US$ Mn), 2021 & 2027
Figure 113: India Market Value Share, By Disease Type, 2021 (E)
Figure 114: India Market Value Share, By Route of Administration, 2021 (E)
Figure 115: ASEAN Market Value Analysis (US$ Mn), 2021 & 2027
Figure 116: ASEAN Market Value Share, By Disease Type, 2021 (E)
Figure 117: ASEAN Market Value Share, By Route of Administration, 2021 (E)
Figure 118: Australia Market Value Analysis (US$ Mn), 2021 & 2027
Figure 119: Australia Market Value Share, By Disease Type, 2021 (E)
Figure 120: Australia Market Value Share, By Route of Administration, 2021 (E)
Figure 121: New Zealand Market Value Analysis (US$ Mn), 2021 & 2027
Figure 122: New Zealand Market Value Share, By Disease Type, 2021 (E)
Figure 123: New Zealand Market Value Share, By Route of Administration, 2021 (E)
Figure 124: GCC Countries Market Value Analysis (US$ Mn), 2021 & 2027
Figure 125: GCC Countries Market Value Share, By Disease Type, 2021 (E)
Figure 126: GCC Countries Market Value Share, By Route of Administration, 2021 (E)
Figure 127: Turkey Market Value Analysis (US$ Mn), 2021 & 2027
Figure 128: Turkey Market Value Share, By Disease Type, 2021 (E)
Figure 129: Turkey Market Value Share, By Route of Administration, 2021 (E)
Figure 130: South Africa Market Value Analysis (US$ Mn), 2021 & 2027
Figure 131: South Africa Market Value Share, By Disease Type, 2021 (E)
Figure 132: South Africa Market Value Share, By Route of Administration, 2021 (E)
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What was the total market worth of ulcerative colitis therapeutics in 2021?
The global ulcerative colitis therapeutics market reached a valuation of US$ 5.86 Bn in 2021.
What is the anticipated CAGR of the global ulcerative colitis therapeutics market over the forecast period?
The global ulcerative colitis therapeutics market is estimated to expand at a CAGR of 5.1% from 2021 to 2027.
Who are the key providers of ulcerative colitis therapeutic products?
Abbott Laboratories, Inc., AstraZeneca PLC, Avaxia Biologics, Inc., BioLineRx Ltd., and Astellas Pharma, Inc. are key providers of ulcerative colitis therapeutic products.
Which are the top 5 countries driving demand for ulcerative colitis therapeutics?
The U.S., Canada, Germany, Japan, and China are expected to drive most demand for ulcerative colitis therapeutics.
What is the sales forecast for ulcerative colitis therapeutics?
The global market for ulcerative colitis therapeutics is expected to be valued at US$ 7.9 Bn by 2027.
Which growth trends are driving global demand ulcerative colitis therapeutic solutions?
High global incidence and prevalence of ulcerative colitis, technological advancements, and increase in patient assistance programs are driving market growth.
Ulcerative Colitis Therapeutics Market